- Home
- TPST vs GBIO Comparison
TPST vs GBIO Comparison
Compare TPST & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- GBIO
- Stock Information
- Founded
- TPST 2011
- GBIO 2016
- Country
- TPST United States
- GBIO United States
- Employees
- TPST N/A
- GBIO N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- GBIO Health Care
- Exchange
- TPST Nasdaq
- GBIO Nasdaq
- Market Cap
- TPST 33.0M
- GBIO 29.5M
- IPO Year
- TPST N/A
- GBIO 2020
- Fundamental
- Price
- TPST $7.71
- GBIO $4.40
- Analyst Decision
- TPST Hold
- GBIO Strong Buy
- Analyst Count
- TPST 3
- GBIO 4
- Target Price
- TPST $30.00
- GBIO $73.33
- AVG Volume (30 Days)
- TPST 94.5K
- GBIO 210.2K
- Earning Date
- TPST 08-07-2025
- GBIO 08-06-2025
- Dividend Yield
- TPST N/A
- GBIO N/A
- EPS Growth
- TPST N/A
- GBIO N/A
- EPS
- TPST N/A
- GBIO N/A
- Revenue
- TPST N/A
- GBIO $24,556,000.00
- Revenue This Year
- TPST N/A
- GBIO N/A
- Revenue Next Year
- TPST N/A
- GBIO N/A
- P/E Ratio
- TPST N/A
- GBIO N/A
- Revenue Growth
- TPST N/A
- GBIO 146.47
- 52 Week Low
- TPST $5.35
- GBIO $3.00
- 52 Week High
- TPST $28.34
- GBIO $35.80
- Technical
- Relative Strength Index (RSI)
- TPST 59.30
- GBIO 53.21
- Support Level
- TPST $7.13
- GBIO $4.28
- Resistance Level
- TPST $8.75
- GBIO $5.10
- Average True Range (ATR)
- TPST 0.45
- GBIO 0.62
- MACD
- TPST 0.13
- GBIO 0.01
- Stochastic Oscillator
- TPST 63.83
- GBIO 30.16
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.